Approximately 11% of all women in western Europe and the USA living to age 80 will develop breast cancer. An annual worldwide incidence of one million is predicted by the year 2000 (Miller and Bulbrook, 1986) . Despite several decades of research, the majority of patients with metastatic breast disease will ultimately fail systemic cytotoxic and endocrine therapies. Clearly, there is a need to identify new and effective treatments for metastatic breast cancer.
The lack of suitable in vitro/in vivo human breast cancer models for drug screening has been a major restriction in the identification of new agents. In previous years, several drug screening programmes have used the P388 and L1210 murine ascites models as a major part of their in vivo programme. The ease of in vitro and in vivo maintenance, and the ability to perform reproducible and rapid estimations of the incidence of long-term survivors and percentage increased lifespan (%ILS), are considered significant advantages. While still frequently used for preclinical drug evaluation, the limitations of the P388 and L1210 models are now widely acknowledged. This reflects their non-human derivation and relatively poor performance in identifying agents active against the more common solid tumours, e.g. breast, lung, colon (Boyd, 1989) .
The current screening at the National Cancer Institute (USA) uses an initial in vitro screen against a panel of human and animal cancer cell lines (Boyd 1989) . Subsequent in vivo screens are performed against these cells growing in rodents. However, new models are needed and these must be amenable to both in vitro and in vivo analyses. The inclusion of additional human breast cancer models with appropriate in vivo and in vitro growth characteristics is critical to the development of a representative panel of models with which to screen agents for anti-tumour activity against breast cancer.
To address several of the concerns associated with using a non-human in vivo screen, e.g. P388, L1210, we have isolated and characterised an ascites model of human breast cancer (MDA435/LCC6). The MDA435/LCC6 ascites were derived from the oestrogen receptor (ER)-negative, invasive and metastatic MDA-MB-435 cell line (Cailleau et al., 1974; Price et al., 1990) . Mice bearing these ascites tumours have a reproducible life span, a pattern of responsiveness to cytotoxic drugs similar to many human breast cancer patients, form rapidly proliferating solid tumours, and are readily adapted for growth in vitro. These cells provide a novel model for the in vitro and in vivo screening of experimental agents for antineoplastic activity against breast cancer.
While many breast tumours are often initially responsive to cytotoxic chemotherapy, the development of a drugresistant phenotype in metastatic breast cancer is ultimately responsible for the failure of current cytotoxic regimens (Clarke et al., 1992a) . Acquired resistance may be associated with expression of the MDR] gene and its gpl70 glycoprotein product (Goldstein et al., 1989) . The level and/or incidence of detectable MDRI/gpl70 expression is significantly higher in the tumours of treated vs untreated breast cancer patients (Schneider et al., 1989; Sanfilippo et al., 1991; Koh et al., 1992) and correlates with in vitro resistance to cytotoxic drugs (Salmon et al., 1989; Sanfilippo et al., 1991; Veneroni et al., 1994 ). The precise role of gpl70 in the clinical resistance of breast and other solid tumours remains to be established. However, it seems likely that where it is clearly expressed it contributes, in some part, to the resistance phenotype. We also wished to establish an appropriate model for screening potential drug resistance modulating agents. We have previously described an ERpositive model of MDR1 resistance, derived by the introduction of the MDR1 cDNA into the hormone-dependent MCF-7 human breast cancer cell line (Clarke et al., 1992b).
To generate a comparable ER-negative model, we have also introduced the MDR1 cDNA into the MDA435/LCC6 ascites cells.
Materials and methods

Cell culture
The parental MDA-MB-435 cells were originally provided by Dr Janet Price (MD Anderson Cancer Center, Houston, TX, USA), and were established from a pleural effusion in a 31-year-old Caucasian woman with metastatic breast cancer (Cailleau et al., 1974 (Cailleau et al., , 1978 . The patient had received no prior systemic therapy (J. Price, personal communication). MDA-MB-435 is one of the few human breast cancer cell lines that produces reproducible lung metastases from solid tumours (Price et al., 1990; Meschter et al., 1992 al., 1988) . Cells were infected with virus by the addition of PA-12 cell supernatant (Pastan et al., 1988) to exponentially proliferating MDA435/LCC6 cells twice, with a 24 h gap between each addition. Transduced cells (1 x 106) were then selected in the presence of either 100 ng ml-' or 400 ng ml-' colchicine for a period of at least 3 months. The stability of the transduced cells was confirmed on removal of the selective pressure. All experiments were performed in cells that had been maintained in the absence of colchicine for at least 3 months. Unless otherwise indicated, all analyses were performed on cells selected against 100 ng ml-' colchicine.
Western blotting
Expression of gpl7O was determined in both transduced and parental MDA435/LCC6 cells by Western blotting with the Ab-l polyclonal anti-gpl70 antibody (Oncogene Science, Cambridge, MA, USA). MCF-7ADR clone 5 cells were included as a positive control. Subconfluent cells (90% confluence) were collected by trypsinisation and counted. The cell pellet was rinsed three times with Dulbecco's phosphatebuffered saline (PBS) and total cellular proteins extracted for 40 min on ice into buffer containing 1% Nonidet P-40, 150 mM sodium chloride, 50 mM Tris-HCl at pH 7.50. Following centrifugation for 5 min at 4°C in a benchtop microfuge, the pellets were discarded and the protein concentration in the supernatant evaluated using the Bradford Assay (Bio-Rad Laboratories, Richmond, CA, USA). Proteins were separated by molecular weight by electrophoresis in sodium dodecyl sulphate/Tris/glycine/polyacrylamide (4-12% gradient) gels and blotted onto nitrocellulose membranes. gp-170 was detected by exposing the nitrocellulose membranes to 155 -~Ascites models of breast cancer rr F Leonessa et al 1lggml-h of the Ab-1 anti-gpl70 antibody (Oncogene Science) for 3 h. The labelled band was detected using the ECL Western blotting detection kit as described by the manufacturer (Amersham, Arlington Heights, IL, USA). (Table III) , with death occurring between days 29-33 post inoculum. In most studies all untreated animals with ascites usually die within 24-48 h of each other. The onset of morbidity also is highly reproducible, and assessment of morbidity rather than death may provide a reliable but more humane end point for many studies.
The tumours grow in the mammary fat pad with an incidence of 100%. The tumour doubling time for MDA435/ LCC6 tumours in nude mice is approximately 2.3 ± 0.7 days, compared with 12 days for ER-positive MCF-7 tumours in oestrogen-supplemented mice (Clarke et al., 1989) . We also have successfully established MDA435/LCC6 solid tumours in NCr rnu/rnu athymic nude rats. The cells exhibit similar tumour growth kinetics in nude rats (2.44 ± 0.6 days) when compared with their growth in nude mice.
Sensitivity of MDA435/LCC6 ascites to cytotoxic drugs The MDA435/LCC6 ascites is sensitive to a range of drugs with known activity against human breast cancer (Table IV) , (Figure 2a) . The MDA435/LCC6MDR' cells, whether selected in 100 ng ml' (Figure 2b ) or 400 ng ml' (Figure 2c) The MDA435/LCC6MDRl cells grow in vivo as both an ascites and as solid tumours (not shown). The growth characteristics of these tumours is similar to that observed in the parental MDA435/LCC6 cells, with the mean survival in untreated mice being 34 ± 3 days (n = 10). These cells appear resistant to DOX in vivo, for which the mean survival was 37 ± 5 days (n = 7; 3 deaths due to toxicity excluded) following treatment with an appropriate DOX regimen (4.0mgkg-' i.p. on days 0, 4, 8, 12 Figure 4 clearly indicate that the IC50 for all three drugs is significantly increased in the MDR1-transduced drug-resistant cells relative to the nontransduced cells. These data also further substantiate the functionality of the expressed gpl7O, and confirm the utility of the MDA435/LCC6MDRl cells as a model for the screening of MDR1-reversing agents.
Discussion
A significant proportion of breast cancer patients (25-50%) develop malignant effusions in the pleural or peritoneal cavities (Fracchia et al., 1970; De Vita, 1989) . In addition to paracentesis for the removal of fluid, some ascites are amenable to intraperitoneal chemotherapy (Fracchia et al., 1970; Goldman et al., 1993) . A significant proportion of all breast tumours (35-40%) are ER negative, and the incidence of ER-negative tumours increased 22-27% over the period [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] (Glass and Hoover, 1990) . When compared with ER-positive tumours, ER-negative tumours are frequently more poorly differentiated (Singh et al., 1988) , proliferate more rapidly (Meyers et al., 1977; Jonat and Maat, 1978) and the patients have a poorer prognosis (Shek and Godlophin, 1989) . We now describe the isolation of the first ascites model of human breast cancer (MDA435/LCC6). We have derived these cells from the ER-negative MDA-MB-435 cell line.
The choice of the MDA-MB-435 cells reflects the relative novelty of several aspects of this cell line. For example, the MDA-MB-435 cells were derived from a pleural effusion in a premenopausal woman (Cailleau et al., 1974 (Cailleau et al., , 1978 who had received no prior systemic therapy (J Price, personal communication). Thus, the MDA-MB-435 cells may have few active endogenous resistance mechanisms and may exhibit a pattern of drug responsiveness similar to the majority of untreated breast cancer patients. This appears to be substantiated by the pattern of response of these cells both in vitro Taxoll (nM) and in vivo to various cytotoxic drugs with diverse mechanisms of action. The MDA-MB-435 cells also are capable of producing distant metastases and occasional ascites from solid mammary fat pad xenografts (Price et al., 1990) and we wished to establish a stable ascites variant. We studied the response of the MDA435/LCC6 ascites to representative agents with known activity in breast cancer patients. To assess the activity of likely endogenous resistance mechanisms, we chose a series of drugs with different mechanisms of action. Thus, we used the anthracycline DOX, which can both generate free radicals and inhibit topoisomerase II (Myers and Chabner, 1990) , the nitrosourea BCNU, which can alkylate DNA (Colvin and Chabner, 1990) , the taxane TAX, which stabilises microtubules (Bender et al., 1990) , the epipodophyllotoxin VP-16, which inhibits topoisomerase II (Bender et al., 1990) , cisplatin, which forms DNA adducts (Reed and Kohn, 1990) , and the antibiotic MITC which can cross-link DNA and generate free radicals (Ghiorghis et al., 1991) . For comparison, two non-cytotoxic treatments were included, saline (the vehicle for most of the drugs) and WR-2721 (Treskes et al., 1991 Green et al., 1992) . Most drugs were administered at or near their anticipated maximum tolerated dose and/or LD10 (Berger et al., 1991) , producing approximately equitoxic treatments. Since BCNU and VP-16 might be expected to have less activity than the other agents against breast cancer cells (Henderson, 1991), these drugs were administered at higher doses. This is evidenced by the increased toxicity of these drugs relative to the others (Table IV) .
The pattern of response to this selection of agents appears to reflect closely that seen in breast cancer patients. For example, breast cancers in general respond poorly to nitrosoureas (Goldman et al., 1993) , and this is mirrored by the poor response of MDA435/LCC6 cells to BCNU. VP-16 also did not produce long-term survivors, and this drug generally has been ineffective as a single agent in breast cancer (Henderson and Shapiro, 1991; Henderson, 1991) . In contrast, DOX (Henderson and Shapiro, 1991) , MITC (Garewal, 1988) and TAX (Donehower and Rowinsky, 1994) The multidrug-resistant phenotype is often accompanied by the expression of the MDR] gene and/or its gpl70 glycoprotein product, both of which are widely detected in treated human breast tumours. Detectable gpl70 expression in breast tumours increases with induction chemotherapy. (Koh et al., 1992) , and correlates with failure of cytotoxic chemotherapy (Goldstein et al., 1989; Sanfilippo et al., 1991) , poor prognosis (Verrelle et al., 1991) , poor survival (Verrelle et al., 1991; Botti et al., 1993) and/or in vitro resistance of human breast cancer biopsies to cytotoxic drugs (Salmon et al., 1989; Sanfilippo et al., 1991) . The precise role of MDR1/ gpl70 in breast cancer remains to be definitively established, but it seems highly likely that in tumours in which expression is detectable this expression contributes to the multidrug- (Moulder and Rockwell, 1987) and excision assays (Hill, 1987 
